title: Prevention by rebamipide of acute reflux esophagitis in rats.
abstract: Proinflammatory factors, including neutrophil-derived oxygen free radicals and inflammatory cytokines, have recently been implicated in the pathogenesis of reflux esophagitis. Rebamipide has been widely used as an anti-ulcer agent. The aim of the present study was to assess the protective effect of rebamipide against acute reflux esophagitis in rats. Esophagitis was induced in rats by ligation at the limiting ridge and the lower portion of the duodenum. Vehicle or rebamipide were given as a single dose intraduodenally. Lesion index (LI), thiobarbituric acid-reactive substances (TBA-RS), myeloperoxidase (MPO) activity, mRNA and protein of tumor necrosis factor (TNF)-alpha and cytokine-induced neutrophil chemoattractant (CINC)-1 in the esophageal mucosa were markedly increased; pretreatment with rebamipide, however, significantly reduced both macroscopic and microscopic injuries and increases in inflammatory mediators. The results of this study indicate that rebamipide protects against the occurrence of esophagitis and has highly promising potential as a new therapeutic agent for reflux esophagitis.
authors.affiliation: Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Katada
authors.forename: Norimasa
authors.initials: N
authors.lastname: Yoshida
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Isozaki
authors.forename: Naoya
authors.initials: N
authors.lastname: Tomatsuri
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ichikawa
authors.forename: Yuji
authors.initials: Y
authors.lastname: Naito
authors.forename: Takeshi
authors.initials: T
authors.lastname: Okanoue
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Yoshikawa
mesh_terms: D000208:Acute Disease; D000409:Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D054360:Chemokine CXCL1; D019743:Chemokines, CXC / Q000502:physiology; D004942:Esophagitis, Peptic / Q000503:physiopathology / Q000517:prevention & control* / Q000662:veterinary; D004947:Esophagus / Q000473:pathology; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology; D015227:Lipid Peroxidation; D008297:Male; D009092:Mucous Membrane; D018375:Neutrophil Activation / Q000187:drug effects; D009195:Peroxidase / Q000378:metabolism; D015363:Quinolones / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
chemical_list: D000897:Anti-Ulcer Agents; D054360:Chemokine CXCL1; D019743:Chemokines, CXC; C513297:Cxcl1 protein, rat; D036341:Intercellular Signaling Peptides and Proteins; D015363:Quinolones; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D009195:Peroxidase; C052785:rebamipide; D000409:Alanine